3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Active not recruiting
10
Completed
9
Recruiting
6
Withdrawn
2
Unknown
2
Terminated
2
Not yet recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Dermatologic
2
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
40
Carcinoma, Non-Small-Cell Lung
35
Carcinoma, Renal Cell
26
Neoplasm Metastasis
19
Lung Neoplasms
18
Carcinoma, Hepatocellular
15
Squamous Cell Carcinoma of Head and Neck
11
Colorectal Neoplasms
11
Pancreatic Neoplasms
10
Neoplasms
9
Carcinoma, Transitional Cell
9
Multiple Myeloma
8
Urinary Bladder Neoplasms
7
Small Cell Lung Carcinoma
7
Head and Neck Neoplasms
7
Breast Neoplasms
7
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
6
Hodgkin Disease
6
Advanced Cancer
6
Myelodysplastic Syndromes
5
Hematologic Neoplasms
5
Brain Neoplasms
5
Skin Neoplasms
4
Recurrence
4
Lymphoma
4
Kidney Neoplasms
4
Glioblastoma
4
Fallopian Tube Neoplasms
4
Uveal Melanoma
3
Interventions
Doxorubicin
13
Gemcitabine
10
Cyclophosphamide
10
pazopanib
8
Filgrastim
8
Radiotherapy
7
Ifosfamide
7
Cisplatin
7
Irinotecan
6
Docetaxel
6
Radiation
5
Granulocyte Colony-Stimulating Factor
5
Etoposide
5
Trabectedin
4
Magnetic Resonance Spectroscopy
4
Celecoxib
4
Busulfan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
temsirolimus
3
sargramostim
3
pembrolizumab
3
X-Rays
3
Sirolimus
3
Radiotherapy, Intensity-Modulated
3
Paclitaxel
3
Neoadjuvant Therapy
3
Leucovorin
3
Dexrazoxane
3
Cryosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Sarcoma
×
Nivolumab
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts